- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.10. | CHMP backs Lilly's oral GLP-1 Foundayo for EU approval | ||
| 16.10. | FDA clears Roche's Enspryng for thyroid eye disease | ||
| 16.10. | RevMed nears EU okay for pancreatic cancer drug Rasonque | ||
| 16.10. | AI in drug discovery & development: News watch, October 2026 | ||
| 15.10. | ImmunityBio bags elusive label extension for Anktiva | ||
| 15.10. | GLP-1 drugs linked to reduced acute schizophrenia episodes | ||
| 15.10. | Roche breast cancer drug Itovebi turned down by NICE | ||
| 15.10. | Could OMass become the UK's 'big biotech' company? | ||
| 14.10. | GSK planning 1,200 job cuts in Belgium, says paper | ||
| 14.10. | MHRA lays out its thinking on AI and medicines regulation | ||
| 14.10. | Zealand forges obesity alliance with AI specialist Generate | ||
| 14.10. | Sanofi escapes fine in EU mismarketing case | ||
| 14.10. | FTC says Shkreli is flouting lifetime pharma ban | ||
| 13.10. | BioNTech sticks with cancer vaccine despite trial miss | ||
| 13.10. | Roche adds another obesity drug with $1.16bn Rona deal | ||
| 13.10. | Bambusa, Aspen and Tang added to IPO pipeline | ||
| 13.10. | Syndax shares fall as lung fibrosis drug fails trial | ||
| 13.10. | Females with autoimmune disease 'less likely to be believed' | ||
| 12.10. | Brent Saunders ejects from Bausch + Lomb once again | ||
| 12.10. | BMS eyes filings for idiopathic pulmonary fibrosis drug | ||
| 12.10. | AZ makes case for hypophosphatasia drug after phase 3 miss | ||
| 12.10. | MSD data reveal undercuts eye drug remigromig's potential | ||
| 12.10. | Lilly's Zepbound enhances Taltz efficacy in psoriasis study | ||
| 12.10. | Aicuris acquisition delivers new drug for Asahi Kasei | ||
| 09.10. | Iambic prices its IPO, seeking to raise up to $160m |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.